Phenotype-Genotype study in 154 French NF2 mutation carriers;Analyse phénotypique de 154 patients porteurs d'une mutation constitutionnelle du gène NF2

Revue Neurologique

Volumn 163, Issue 11, 2007, Pages 1031-1038

  Demange, L ^a   De Moncuit, C ^b   Thomas, G ^c   Olschwang, S ^d  

^a CENTRE RENÉ HUGUENIN   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

Genotype; Germline mutation; Neurofibromatosis type 2; Phenotype; Risk assessment

Indexed keywords

MERLIN;

ADULT; ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; FRAMESHIFT MUTATION; FRANCE; GENE MUTATION; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MISSENSE MUTATION; MORTALITY; NEURILEMOMA; NEUROFIBROMATOSIS; PHENOTYPE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SPINAL CORD TUMOR; STATISTICAL ANALYSIS; SYMPTOMATOLOGY;

EID: 37149013042     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(07)74175-9     Document Type: Article

References (21)

1. BASER ME, FRIEDMAN JM, AESCHLIMAN D. (2002a). Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet, 71: 715-723.
2. BASER ME, FRIEDMAN JM, WALLACE AJ, RAMSDEN RT, JOE H, EVANS DG. (2002b). Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology, 59: 1759-1765.
3. BASER ME, KURAMOTO L, JOE H, FRIEDMAN, et al. (2004). Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet, 75: 231-239.
4. BASER ME, RAGGE NK, RICARDI VM, JANUS T, GANTZ B AND PULST SM. (1996). Phenotypic variability in monozygotic twins with neurofibromatosis. Am J Hum Genet, 64: 563-567.
5. BOURN D, CARTER SA, MASON S, EVANS DGR, STRACHAN T. (1994). Germline mutations in the neurofibromatosis type 2 tumor suppressor gene. Hum Mol Genet, 3: 813-816.
6. CHARBONNIER F, RAUX G, WANG Q, et al. (2000). Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res, 60: 2760-2763.
7. EVANS DGR, HUSON SM, DONNAI D, et al. (1992a). A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet, 29: 841-846.
8. EVANS DGR, HUSON SM, DONNAI D, et al. (1992b). A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet, 29: 847-852.
9. GUTMANN DH, AYLSWOTH A, CAREY JC, et al. (1997). The diagnostic evaluation and multidisciplinary management of neurofibromatosis type 1 and neurofibromatosis type 2. JAMA, 278: 51-57.
10. KLUWE L, MAC COLLIN M, TATAGIBA M. (1998). Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet, 77: 223-228.
11. KLUWE L, MAUTNER VF. (1996). A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type. Hum Genet, 97: 224-227.
12. MEREL P, HOANG-XUANG K, SANSON M, et al. (1993). Screening for germ-line mutations in the NF2 gene. Gene Chromosom Cancer, 12: 117-1127.
13. PARRY DM, MAC COLLIN MM, KAISER- KUPFER MI, et al. (1996). Germline mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet, 59: 529-539.
14. PATRONAS NJ, COURCOUTSAKIS N, BROMLEY CM. (2001). Intramedullary and spinal canal tumors in patients with neurofibromatosis 2. MR imaging findings and correlation with genotype. Radiology, 218: 434-442.
15. ROULEAU GA, MEREL P, LUTCHAMN M, et al. (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature, 363: 515-521.
16. RUTTLEDGE MH, ANDERMANN AA, PHELAN CM, et al. (1996). Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet, 59: 331-342.
17. SANSON M, MARINEAU C, DESMAZE C, et al. (1993). Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Hum Mol Genet, 2: 1215-1220.
18. SCOLES DR, BASER ME, PULST SM. (1996). A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology, 47: 544-546.
19. WATSON CJ, GAUNT L, EVANS G, PATEL K, HARRIS R, STRACHAN T. (1993). A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitor factor locus. Hum Mol Genet, 2: 701-704.
20. ZHAO Y, KUMAR RA, BASER ME. (2002). Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genet Epidemiol, 23: 245-259.
21. ZUCMAN-ROSSI J, LEGOIX P, DER SARKISSIAN H, et al. (1998). NF2 gene in neurofibromatosis type 2 patients. Hum Molec Genet, 7: 2095-2101.